[1] SMITH SM. Impact of Double-Hit and Double-Expressor Phenotypes in Relapsed Aggressive B-Cell Lymphomas Treated With Autologous Hematopoietic Stem Cell Transplantation. J Clin Oncol. 2017;35(1):1-3.
[2] TUCHMAN SA, BACON WA, HUANG LW, et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J Clin Apher. 2015;30(3):176-182.
[3] YEH JC, SHANK BR, MILTON DR, et al. Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis. Biol Blood Marrow Transplant. 2018;24(4):815-819.
[4] 廖丽昇,郑志海,魏天南,等.DA-EPOCH与MA方案在非霍奇金淋巴瘤自体外周造血干细胞动员中的临床观察[J].中华医学杂志,2018,98(26):2099-2103.
[5] 赵志强,王列样,刘小兰,等.自体外周血干细胞动员及采集效果影响因素分析[J].白血病•淋巴瘤,2019,28(9):533-537.
[6] KRIEGSMANN K, WUCHTER P. Mobilization and Collection of Peripheral Blood Stem Cells in Adults: Focus on Timing and Benchmarking. Methods Mol Biol. 2019;2017:41-58.
[7] 中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会白血病淋巴瘤学组,中国临床肿瘤学会抗淋巴瘤联盟.造血干细胞移植治疗淋巴瘤中国专家共识(2018版)[J].中华肿瘤杂志,2018,40(12):927-934.
[8] 郭智,刘晓东,杨凯,等.allo-HSCT并使用高剂量环磷酰胺诱导免疫耐受治疗重型再生障碍性贫血[J].中华器官移植杂志,2015,36(6):356-361.
[9] 郭智,童春,刘晓东,等.单倍型异基因造血干细胞移植后大剂量环磷酰胺诱导免疫耐受治疗儿童重型再生障碍性贫血[J].中国组织工程研究,2016, 20(32):4818-4824.
[10] 万鼎铭,刘郁叶,曹伟杰,等.亲缘单倍体外周血造血干细胞移植治疗骨髓增生异常综合征:2年21例随访[J].中国组织工程研究,2018,22(5):662-668.
[11] GUO Z, GAO HY, ZHANG TY, et al. Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia. Int J Hematol. 2016;104(6):720-728.
[12] TAKAMI A. Hematopoietic stem cell transplantation for acute myeloid leukemia. Int J Hematol. 2018;107(5):513-518.
[13] GAO L, XIANG X, ZHANG C, et al. Upfront autologous hematopoietic stem cell transplantation in patients with high-risk stage III to IV Hodgkin lymphoma: a multicenter retrospective cohort study. Hematology. 2019;24(1):225-231.
[14] 刘卫平,吴梦,张晨,等.自体造血干细胞移植治疗老年淋巴瘤19例的疗效及安全性[J].中华血液学杂志,2018,39(12):1033-1036.
[15] DUONG HK, SAVANI BN, COPELAN E, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20(9):1262-1273.
[16] TANIMURA A, HIRAI R, NAKAMURA M, et al. Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone. Int J Hematol. 2018;107(5): 559-567.
[17] 孙巍,高敏,谢嵘,等.151例淋巴瘤外周血造血干细胞采集影响因素分析[J].中国实验血液学杂志,2016,24(2):416-421.
[18] 张红,周芳,宋媛,等.自体造血干细胞移植患者外周血造血干细胞采集影响因素[J].白血病•淋巴瘤,2019,28(1):50-51.
[19] 王国蓉,陈文明,李燕郴,等.149例多发性骨髓瘤患者自体外周血造血干细胞动员采集的回顾性分析[J].中华血液学杂志,2015,36(5):367-371.
|